SERUM SPLA2-IIA AS DIAGNOSIS MARKER FOR PROSTATE AND LUNG CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 1, 2012
app pub date -
Jan 5, 2011
filing date -
Jan 5, 2010
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Methods for diagnosing prostate cancer and lung cancer are disclosed. The methods include obtaining a biological sample from a subject, determining a level of serum secretory phospholipase A2-IIA in the biological sample, comparing the level of serum secretory phospholipase A2-IIA with a baseline level of serum secretory phospholipase A2-IIA, and diagnosing prostate cancer or lung cancer in the subject. An elevated level of serum secretory phospholipase A2-IIA as compared to the baseline level correlates to a positive diagnosis of prostate cancer or lung cancer in the subject.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully